Abstract
In Europe more than 3 million individuals develop a malignancy annually. Despite recent progress in screening, diagnosis and therapy of most cancers, prognosis remains poor and only a minority of patients are cured. This owes to the fact that most cancers are diagnosed in advanced stages and due to the fact that treatment options for most cancers are limited. While there has been a substantial improvement in systemic therapy for many cancers it remains difficult to assess the potential responsiveness of the cancers towards these newly developed drugs, which include small molecules and monoclonal antibodies. Therefore various strategies have been developed in order to assess the prognosis and predict the expected tumor response in order to individualize the treatment, thereby offering the patient a tailored therapy which accounts for the tumor- and patient-specific morphological and molecular characteristics of the disease. This review summarizes recent efforts, challenges and limitations of proteome analysis in the assessment of prognosis and response-prediction in human cancers.
Keywords: Proteomics, translational oncology, prediction, prognosis, biomarker
Current Cancer Drug Targets
Title: Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Volume: 8 Issue: 2
Author(s): Christoph Rocken, Ralf Ketterlinus and Matthias P.A. Ebert
Affiliation:
Keywords: Proteomics, translational oncology, prediction, prognosis, biomarker
Abstract: In Europe more than 3 million individuals develop a malignancy annually. Despite recent progress in screening, diagnosis and therapy of most cancers, prognosis remains poor and only a minority of patients are cured. This owes to the fact that most cancers are diagnosed in advanced stages and due to the fact that treatment options for most cancers are limited. While there has been a substantial improvement in systemic therapy for many cancers it remains difficult to assess the potential responsiveness of the cancers towards these newly developed drugs, which include small molecules and monoclonal antibodies. Therefore various strategies have been developed in order to assess the prognosis and predict the expected tumor response in order to individualize the treatment, thereby offering the patient a tailored therapy which accounts for the tumor- and patient-specific morphological and molecular characteristics of the disease. This review summarizes recent efforts, challenges and limitations of proteome analysis in the assessment of prognosis and response-prediction in human cancers.
Export Options
About this article
Cite this article as:
Rocken Christoph, Ketterlinus Ralf and Ebert P.A. Matthias, Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology, Current Cancer Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/156800908783769328
DOI https://dx.doi.org/10.2174/156800908783769328 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Nucleic Acid Aptamers Based on the G-Quadruplex Structure: Therapeutic and Diagnostic Potential
Current Medicinal Chemistry <i>TGF-β1</i>-based CRISPR/Cas9 Gene Therapy Attenuates Radiation-induced Lung Injury
Current Gene Therapy Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Cytology for the Detection of Early Recurrence of Gynecologic Cancer in the Vaginal Vault
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of Anti-Inflammatory and Antitussive Activity of Hydantion Derivatives
Letters in Drug Design & Discovery Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Protein-Based Voltammetric Biosensors Fabricated with Nanomaterials
Protein & Peptide Letters